Sugi Predict

Sugi Predict / Compounds / SCHEMBL1553262

SCHEMBL1553262

SCHEMBL1553262

O=C1COCCN1Cc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 1/20 0.54
▸ DDB1 Q16531 1/20 0.46
▸ CRBN Q96SW2 1/20 0.46
▸ TSHR P16473 2/20 0.46
▸ KMT2A Q03164 2/20 0.45
▸ CYP2D6 P10635 2/20 0.45
▸ CYP2C9 P11712 2/20 0.45
▸ CYP2C19 P33261 2/20 0.45
▸ POLB P06746 1/20 0.45
▸ MEN1 O00255 1/20 0.45
▸ PRMT5 O14744 1/20 0.45
▸ WDR77 Q9BQA1 1/20 0.45
▸ DRD3 P35462 1/20 0.44
▸ KCNH2 Q12809 1/20 0.44
▸ HPGD P15428 1/20 0.44
▸ JAK2 O60674 1/20 0.43
▸ CYP1A2 P05177 1/20 0.43
▸ CYP3A4 P08684 1/20 0.43
▸ SIGMAR1 Q99720 1/20 0.42
▸ F2 P00734 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2794226 0.90 L3MBTL1 (0.59) L3MBTL1DDB1CRBNTSHRKMT2A
SCHEMBL22594754 0.87 L3MBTL1 (0.52) L3MBTL1DDB1CRBNTSHRKMT2A
SCHEMBL25081031 0.85 L3MBTL1 (0.61) L3MBTL1DDB1CRBNTSHRKMT2A
SCHEMBL20425267 0.85 JAK2 (0.43) L3MBTL1PRMT5WDR77JAK2
SCHEMBL8325711 0.83 GRM2 (0.54) L3MBTL1KMT2APOLBMEN1JAK2
SCHEMBL79013 0.83 GRM2 (0.43) L3MBTL1PRMT5WDR77JAK2LMNA
SCHEMBL23269469 0.83 KMT2A (0.46) L3MBTL1KMT2AMEN1JAK2PTGS2
SCHEMBL13299412 0.83 SMN1; SMN2 (0.49) TSHRKMT2APOLBMEN1JAK2
SCHEMBL28650553 0.83 JAK2 (0.40) L3MBTL1PRMT5WDR77JAK2
SCHEMBL2282613 0.83 PTGS1 (0.46) L3MBTL1KMT2APOLBMEN1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3027601-B1 SYK INHIBITORS GILEAD SCIENCES INC (US) 2017-10-25 — — EP claimed
US-20160368918-A1 SYK INHIBITORS Kronos Bio, Inc. 2016-12-22 — — US claimed
EP-3027601-A1 SYK INHIBITORS Gilead Sciences, Inc. (US) 2016-06-08 — — EP claimed
WO-2015017610-A1 SYK INHIBITORS GILEAD SCIENCES, INC. (US) 2015-02-05 — — WO claimed
US-20150038488-A1 SYK INHIBITORS Kronos Bio, Inc. 2015-02-05 — — US claimed
EP-1910320-A2 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF Mitsubishi Tanabe Pharma Corporation (JP) 2008-04-16 — — EP claimed
WO-2007011065-A2 INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF MITSUBISHI TANABE PHARMA CORPORATION (JP) 2007-01-25 — — WO claimed
EP-4653438-A1 MACROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF Genfleet Therapeutics (Shanghai) Inc. (CN) 2025-11-26 — — EP disclosed
WO-2025129104-A1 COMPOUNDS, COMPOSITIONS, AND METHODS OF USING THEREOF SIONNA THERAPEUTICS INC. (US) 2025-06-19 — — WO disclosed
US-12281101-B2 Bicyclic lactams and methods of use thereof GENENTECH, INC. (US) 2025-04-22 — — US disclosed
CN-117777048-B Preparation method of chiral 2-hydroxymethylmorpholine-4-carboxylic acid tert-butyl ester 上海科利生物医药有限公司 2024-09-20 — — CN disclosed
WO-2024153208-A9 MACROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF 劲方医药科技(上海)有限公司 2024-08-22 — — WO disclosed
WO-2024153208-A1 MACROCYCLIC COMPOUNDS, PREPARATION METHOD THEREFOR, AND USE THEREOF 劲方医药科技(上海)有限公司 2024-07-25 — — WO disclosed
US-20030130264-A1 Methods of using pyrimidine-based antiviral agents TULARIK INC. (US) 2003-07-10 — — US disclosed
US-20030045715-A1 Arylsulfonic acid salts of pyrimidine-based antiviral agents TULARIK INC. (US) 2003-03-06 — — US disclosed
EP-1248783-A1 ARYLSULFONIC ACID SALTS OF PYRIMIDINE-BASED ANTIVIRAL AGENTS Tularik Inc. (US) 2002-10-16 — — EP disclosed
WO-2002064096-A2 METHODS OF USING PYRIMIDINE-BASED ANTIVIRAL AGENTS TULARIK INC. (US) 2002-08-22 — — WO disclosed
US-6410726-B1 USEFUL IN TREATING AND SUPPRESSING HUMAN CYTOMEGALOVIRUS TULARIK INC. 2002-06-25 — — US disclosed
US-20020065279-A1 Useful in treating and suppressing human Cytomegalovirus AMGEN INC. 2002-05-30 — — US disclosed
WO-2001051485-A1 ARYLSULFONIC ACID SALTS OF PYRIMIDINE-BASED ANTIVIRAL AGENTS TULARIK INC. (US) 2001-07-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020065279-A1 Useful in treating and suppressing human Cytomegalovirus TPMT, MGMT, NSUN2 L3MBTL1 3005/4885DDB1 892/4885CRBN 1435/4885
US-20030130264-A1 Methods of using pyrimidine-based antiviral agents TYMP, TYMS, NUDT1 L3MBTL1 2573/4885DDB1 233/4885CRBN 2729/4885
US-12281101-B2 Bicyclic lactams and methods of use thereof LSS, LPXN, CYP1B1 L3MBTL1 2686/4885DDB1 3633/4885CRBN 546/4885
US-20150038488-A1 SYK INHIBITORS SYK, BTK, LYN L3MBTL1 1882/4885DDB1 2537/4885CRBN 630/4885
US-20030045715-A1 Arylsulfonic acid salts of pyrimidine-based antiviral agents PNP, TPMT, NSUN2 L3MBTL1 3736/4885DDB1 856/4885CRBN 2105/4885
US-20160368918-A1 SYK INHIBITORS SYK, BTK, LYN L3MBTL1 2129/4885DDB1 2373/4885CRBN 638/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.